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Visual dysfunction in Parkinson’s disease
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Patients with Parkinson’s disease have a number of speciﬁc visual disturbances. These include changes in colour vision and contrast
sensitivity and difﬁculties with complex visual tasks such as mental rotation and emotion recognition. We review changes in visual
function at each stage of visual processing from retinal deﬁcits, including contrast sensitivity and colour vision deﬁcits to higher
cortical processing impairments such as object and motion processing and neglect. We consider changes in visual function in
patients with common Parkinson’s disease-associated genetic mutations including GBA and LRRK2. We discuss the association
between visual deﬁcits and clinical features of Parkinson’s disease such as rapid eye movement sleep behavioural disorder and the
postural instability and gait disorder phenotype. We review the link between abnormal visual function and visual hallucinations,
considering current models for mechanisms of visual hallucinations. Finally, we discuss the role of visuo-perceptual testing as a
biomarker of disease and predictor of dementia in Parkinson’s disease.
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Introduction
The contribution of non-motor symptoms to a reduced
quality of life in Parkinson’s disease is now widely recog-
nized. In addition to complaints attributable to autonomic,
gastrointestinal and cognitive dysfunction, visual symptoms
are frequently reported (Davidsdottir et al., 2005).
Although many groups have demonstrated changes in
visual perception in Parkinson’s disease, until now, most
of these have focused on changes attributed to ophthalmic
pathology. Here, we review the changes in visual
perception in Parkinson’s disease under four separate sec-
tions. First we examine the evidence for visual deﬁcits from
early sensory discrimination to higher visual dysfunction.
Second, we consider the neurobiology underlying visual
changes including location of deﬁcits and associated genetic
mutations. Third, we examine the link between visual dys-
function and other clinical manifestations such as visual
hallucinations and consider current theories of visual hal-
lucinations. Finally we consider the role for testing visual
perceptual function in early detection of dementia in
Parkinson’s disease.
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The scope of the problem of vision
in Parkinson’s disease
Patients with Parkinson’s disease frequently report prob-
lems with visual tasks, such as navigating around everyday
environments and using maps (Bowen et al., 1972;
McDowell and Harris, 1997b; Davidsdottir et al., 2005).
In questionnaire studies, 78% of patients with Parkinson’s
disease report at least one visual symptom, including difﬁ-
culty reading, sometimes with double vision, and misjud-
ging objects and distances (Archibald et al., 2011; Urwyler
et al., 2014). Visual hallucinations are also common in
Parkinson’s disease, with a reported prevalence as high as
74% after 20 years of disease (Fenelon et al., 2000; Hely
et al., 2008). The underlying mechanisms are still not well
understood, despite multiple proposed mechanisms (Barnes
et al., 2003; Collerton et al., 2005; Diederich et al., 2014;
Shine et al., 2014). A deeper understanding of changes in
visual perception in Parkinson’s disease will greatly en-
hance our ability to manage visual hallucinations. Visuo-
perceptual problems are well described in dementia with
Lewy bodies and in Parkinson’s disease dementia, but
there is growing evidence pointing to changes in visual pro-
cessing earlier in the disease course. Here we examine
changes in visual processing that are seen in patients with
Parkinson’s disease and no other cognitive deﬁcits. The
studies cited here involve patients in the mid-stages of
Parkinson’s disease at an average Hoehn and Yahr stage
of 2 while on their regular Parkinson’s drugs, unless stated
otherwise.
Evidence for changes in visual
processing
Ophthalmic visual processing: visual
acuity
Visual acuity is the ability to resolve the details of a stimu-
lus and is affected by ophthalmic factors, including retinal
deﬁcits, rather than cortical disease. See Fig. 1 for an over-
view of the functional anatomy of healthy vision. Visual
acuity may be impaired in Parkinson’s disease (Jones
et al., 1992; Archibald et al., 2011), and this effect is not
corrected by dopamine. Higher scores on parkinsonian
motor examination may predict poor visual acuity
(Archibald et al., 2011). However, the differences are
small (Jones et al., 1992) and are not seen in early stage
untreated patients (Biousse et al., 2004) or in some studies
involving mid-stage patients (Regan and Maxner, 1987),
although in many studies acuity is regarded as normal if
it is 6/9 or better (Bodis-Wollner et al., 1987) or is con-
sidered on a case-by-case basis, which may miss subtle
group differences in acuity.
Contrast sensitivity
Contrast sensitivity is the ability to discriminate an ob-
ject from its background and is affected by lesions in
the eye (including retina) as well as in thalamic or cortical
locations. In tests using vision charts with letters of the
same size but reducing contrast, patients with Parkinson’s
disease have normal acuity but impaired contrast
detection (Regan and Neima, 1984) (Fig. 2A and B).
With more quantitative measurements, patients with
Parkinson’s disease show loss of contrast sensitivity
across a range of spatial frequencies and in both foveal
(central) and peripheral locations (Silva et al., 2005).
Contrast sensitivity loss is partly reversible with L-DOPA
treatment, in both early (Bulens et al., 1987) and mid-stage
Parkinson’s disease (Bodis-Wollner et al., 1987) but it even-
tually deteriorates again as the disease advances (Diederich
et al., 2002).
Colour vision
In the healthy brain, colour is processed by photoreceptor
cones in the retina and at higher levels from primary visual
Figure 1 Functional anatomy of healthy human vision.
Information passes from the retina, via the optic nerve and optic
tract to the lateral geniculate nucleus (LGN) in the thalamus. From
there, signals project via the optic radiation to the primary visual
cortex (V1). Cells in V1 process simple local attributes such as the
orientation of lines and edges. From primary visual cortex, infor-
mation is organized as two parallel hierarchical processing streams:
the ventral stream identifies features of objects and passes from V1
through areas V2 and V4 to the inferior temporal cortex. The
dorsal stream processes spatial relations between objects and
projects through areas V2 and V3 to the superior temporal and
parietal cortices. Almost all connections between regions are re-
ciprocal, with further feedback projections from areas outside this
pathway. IT = infero-temporal region; MT/V5 = motion processing
region. Adapted from Manassi et al. (2013) with permission (copy-
right held by the Association for Research in Vision and
Ophthalmology).
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cortex (V1) to extra-striate visual cortex (V4). Disordered
colour discrimination is recognized in Parkinson’s disease
(Price et al., 1992; Buttner et al., 1995), even in the early
stages of the disease, in untreated patients (Buttner et al.,
1995). Abnormalities in colour vision have also been cor-
related with axial motor symptoms (Oh et al., 2011), with
motor speed (in untreated patients) (Muller et al., 1999)
and with disease duration (Price et al., 1992). Colour
vision deﬁcits progress over time in both treated and un-
treated patients (Diederich et al., 2002; Muller et al.,
2002). Colour discrimination may be confounded by cog-
nitive or motor deﬁcits in some studies (Regan et al., 1998),
due to the length of time needed to administer the widely
used Farnsworth-Munsell 100 Hue test. This test requires
patients to arrange 100 coloured discs in sequence. Colour
discrimination, as measured in this way, correlates with
cognitive performance and with white matter changes in
posterior brain structures (Bertrand et al., 2012).
However, abnormalities in colour vision can also be
found using tests that are less susceptible to these con-
founds (Silva et al., 2005). Colour loss, when measured
in this way, is distinct from normal ageing and seems to
particularly affect the protan and deutan (red–green) axes
(Silva et al., 2005), although other investigators have found
greatest deﬁcits in the tritan (blue–yellow) axis (Haug et al.,
1995; Regan et al., 1998). It is unclear whether colour
vision abnormalities in Parkinson’s disease reﬂect retinal
or cortical disease, but given that differences can be seen
along several axes (Silva et al., 2005), it is likely that
changes in colour sensitivity are multifactorial.
Are visual abnormalities in
Parkinson’s disease due to retinal
dysfunction?
Deﬁcits in visual acuity, contrast and colour in Parkinson’s
disease are at least partly due to retinal dopamine deﬁ-
ciency. The healthy human retina contains dopaminergic
amacrine cells (Frederick et al., 1982) and patients with
Parkinson’s disease have reduced dopamine innervation
around the fovea (Nguyen-Legros, 1988). Autopsy studies
show decreased retinal dopamine concentrations in
Parkinson’s disease (Harnois and Di, 1990). The inner
Figure 2 Measuring visual function: visual contrast sensitivity. (A) Pelli-Robson Chart for measuring contrast sensitivity. Letters are of
the same size but reducing contrast (Pelli et al., 1988). (B) A Campbell-Robson grating, showing increasing spatial frequency plotted against
decreasing contrast. Visibility is indicated by the inverted U-shaped curve, with maximal visibility at mid-range spatial frequency, although
individuals vary in their precise point of visibility (Campbell and Robson, 1968). (C) Loss of contrast sensitivity at the middle range of spatial
frequencies in Parkinson’s disease. Example contrast sensitivity curve for a patient with Parkinson’s disease (each line represents one eye).
Adapted from Bulens et al. (1986) with permission. (D) Effect of orientation of visual grating on contrast sensitivity in Parkinson’s disease.
Contrast sensitivity for perception of gratings at orientations ranging from vertical (0 degrees), through horizontal (90 degrees) and back to
vertical (180 degrees). Reduced contrast sensitivity is seen for horizontal gratings. Adapted from Regan and Maxner (1987) with permission.
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retinal layer is thinner in patients with Parkinson’s disease,
measured using optical coherence tomography (Hajee et al.,
2009). Retinal electrical activity is decreased compared to
healthy controls, measured by electroretinogram (Tagliati
et al., 1996; Moschos et al., 2011) and improves with L-
DOPA treatment (Peppe et al., 1995). Intriguingly, patients
with Parkinson’s disease have shorter durations of negative
afterimages than healthy controls (Khadjevand et al.,
2010), a process thought to be mediated in health by ret-
inal dopaminergic neuromodulation (Wink and Harris,
2000). In some patients, contrast sensitivity thresholds
and visual evoked potential latencies differ between eyes
(Bulens et al., 1986, 1987; Bodis-Wollner et al., 1987),
raising the likelihood of prechiasmal involvement. The
recent ﬁnding in the inner retinal layer of misfolded -synu-
clein (Bodis-Wollner et al., 2014a) and of phosphorylated
-synuclein (Beach et al., 2014), the pathological hallmark
of Parkinson’s disease, is striking evidence of retinal in-
volvement in Parkinson’s disease. At least some aspects of
visual dysfunction in Parkinson’s disease therefore involve
disruption of processing at the level of the retina.
Some untreated patients also show loss of contrast sensi-
tivity at speciﬁc intermediate spatial frequencies (Fig. 2C)
(Bulens et al., 1986). This is more suggestive of a cortical
rather than retinal or geniculate site of disruption as cor-
tical neurons show stronger selectivity for different spatial
frequencies than neurons in the retina or thalamus
(Campbell and Robson, 1968; De Valois et al., 1982;
Regan, 1982). In addition to spatial frequency selectivity,
contrast sensitivity in Parkinson’s disease is often orienta-
tion-speciﬁc, with greatest deﬁcits for horizontal gratings
(Regan and Maxner, 1987; Bulens et al., 1988; Trick
et al., 1994) (Fig. 2D). As receptive ﬁelds of neurons in
primary visual cortex are tuned to speciﬁc orientations
(Hubel et al., 1978), these ﬁndings implicate primary
visual cortex as the locus for deﬁcits in contrast sensitivity
in Parkinson’s disease, rather than just the retina or the
thalamus, which are not linked to orientation speciﬁcity.
Changes in eye movements
Subtle oculomotor changes can be seen in Parkinson’s dis-
ease, with voluntary saccades particularly affected. Latency
and velocity are preserved but amplitude is reduced, produ-
cing hypometric movements (Ventre et al., 1992; Kimmig
et al., 2002; MacAskill et al., 2002). Saccades to a remem-
bered target are particularly impaired and show a multistep
pattern (Crawford et al., 1989). These are thought to arise
from deﬁcits in oculomotor pathways in the brainstem,
cerebellum, basal ganglia and frontal lobes. In addition,
patients with Parkinson’s disease commonly show conver-
gence insufﬁciency, that impacts on near activities and may
lead to double vision on reading (Almer et al., 2012;
Nowacka et al., 2014). Pronounced oculomotor abnormal-
ities, when present, usually indicate an atypical
Parkinsonian syndrome, but supranuclear vertical gaze im-
pairment has rarely been reported in pathologically
conﬁrmed Parkinson’s disease. Early decreased saccadic vel-
ocity, preservation of saccadic latency and paresis of verti-
cal saccades favour a diagnosis of progressive supranuclear
gaze palsy (Bhidayasiri et al., 2001). Cerebellar type eye
movement abnormalities, such as gaze-evoked nystagmus,
abnormal vestibulo-ocular-reﬂex suppression, down-beat
nystagmus, and excessive square wave jerks are more sug-
gestive of multiple system atrophy (for a review see
Pinkhardt and Kassubek, 2011).
Visual processing in early cortical
visual areas: line orientation, pattern
perception and depth perception
The earliest stages of cortical visual processing involve dis-
crimination of local attributes. Neurons in primary visual
cortex (V1) are sensitive to the orientation of lines and
edges (Fig. 1) and changes in visual acuity and contrast
sensitivity in patients with Parkinson’s disease, may be
caused by deﬁcits in early cortical visual processing. In
tests comparing the ability to distinguish between lines of
differing directions (Benton et al., 1978), several studies
showed impaired performance in patients with
Parkinson’s disease (Montse et al., 2001; Uc et al., 2005;
Gullett et al., 2013) that correlated with duration and se-
verity of disease. Although primary visual cortex is sensitive
to changes in line orientation, judgements of matching lines
may also involve higher order visuospatial processing.
Indeed, in lesion studies of non-parkinsonian patients, fail-
ure in orientation judgements is most strongly associated
with parietal lobe lesions (Tranel et al., 2009).
Pattern perception and ﬁgure ground discrimination in-
volve a combination of earlier visual cortical processing
and higher level interpretation. In tasks requiring comple-
tion of patterns, patients with Parkinson’s disease perform
worse than healthy controls (Flowers and Robertson,
1995). Similarly, patients performing a ﬁgure–ground dis-
crimination task (identifying ﬁgures embedded in more
complex ﬁgures) made more errors than healthy controls
(especially those with more advanced disease) (Flowers and
Robertson, 1995). In neuroimaging studies, patients with
worse performance in similar tasks also have reduced
grey matter density in their superior parietal lobes
(Pereira et al., 2009).
Depth perception is also affected in patients with
Parkinson’s disease and is associated with worse motor
dexterity and decreased colour perception (Sun et al.,
2014). Untreated Parkinson’s patients with impaired
depth perception have been shown, in neuroimaging stu-
dies, to have reduced grey matter volume in visual associ-
ation areas (Koh et al., 2013).
Peripheral vision
Information from peripheral visual ﬁelds is processed at
multiple levels from the retina to higher cortical regions.
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When patients are given a visual task, and presented with
distracting images in their peripheral ﬁelds at the same
time, the irrelevant peripheral objects interfere with the
main task to a much greater extent than they do for
healthy volunteers (McDowell and Harris, 1997a).
Conversely, although patients with Parkinson’s disease are
more distracted by targets shown in the periphery, they
have greater difﬁculty discriminating details of peripheral
images and perceive these images less strongly than healthy
volunteers (Harris et al., 1992; Sampaio et al., 2011). A
combination of reduced contrast sensitivity in the periphery
with greater distraction from peripheral objects may pro-
vide a perceptual explanation for the common phenomenon
of freezing in doorways and crowded surroundings seen in
the later stages of Parkinson’s disease in many patients
(McDowell and Harris, 1997a).
Object perception
In the healthy brain, object processing occurs in V2, V4
and the lateral occipital complex, especially in the right
hemisphere (Grill-Spector et al., 1999; Kourtzi and
Kanwisher, 2000; Large et al., 2007). Patients with early
stage Parkinson’s disease are as good at recognizing
common objects from silhouettes as healthy controls
(Hipp et al., 2014). However, by mid-stage, they start to
have difﬁculties in identifying overlapping objects (Pillon
et al., 1989; Mosimann et al., 2004), with worse perform-
ance occurring in patients with left-sided motor
symptoms (Levin et al., 1991). This is consistent with
right hemisphere predominance in object recognition and
suggests asymmetry in cortical as well as nigral
involvement.
Mental rotation is another aspect of object recognition
that may be affected in Parkinson’s disease. In a previous
small study, patients with Parkinson’s disease made more
errors when matching objects in 3D space (Lee et al.,
1998). Greater differences were seen at larger angular dis-
crepancies, when objects were more rotated, suggesting that
the abnormality is caused by changes in the mental ability
to rotate objects, rather than simply due to differences in
pattern matching. Although error rates were not increased
when objects were rotated in 2D space, responses were
slower, suggesting some impaired performance for 2D ro-
tation. A recent large study found impaired performance in
2D rotation in patients with early stage Parkinson’s disease,
with even greater impairments in patients carrying the H1
MAPT haplotype (microtubule-associated protein tau), par-
ticularly in more difﬁcult forms of the task (Nombela et al.,
2014) (see below for further discussion on genetic
associations).
Visuospatial construction
Patients with Parkinson’s disease make more errors when
copying and recalling complex ﬁgures than healthy controls
(Ogden et al., 1990; Uc et al., 2005). Copying intersecting
pentagons is frequently used as a simple bedside measure of
visuospatial function in Parkinson’s disease. It is quick to
perform and is a component of the Mini-Mental State
Examination (Williams-Gray et al., 2013; Lawson et al.,
2014). Longitudinal studies show that it has value in pre-
dicting the development of dementia in Parkinson’s disease.
In a recent large cross-sectional study, patients with
Parkinson’s disease showed slightly lower scores for copy-
ing intersecting pentagons than healthy controls (Garcia-
Diaz et al., 2014), with a correlation between performance
in pentagon copying and reduced cortical thickness in par-
ieto-temporal regions. However, no difference was seen by
another group using a less detailed scoring system and
fewer patients (Filoteo et al., 2014). This highlights the
relatively low sensitivity of this test in assessing visuospatial
performance. In clock drawing tests, patients with
Parkinson’s disease (and no dementia) make more errors
than healthy controls (Dal et al., 1989; Stella et al.,
2007; Saur et al., 2012) and errors in drawing houses are
also reported in Parkinson’s disease (Kulkarni et al., 2013).
However, all these tests lack speciﬁcity for visuospatial
function as they involve several cognitive domains in add-
ition to visuospatial processing, including praxis, memory
and executive function.
Motion perception
Parkinson’s disease impairs the perception of motion,
which is strongly linked with the middle temporal area
MT/V5 (Zeki et al., 1991; Tootell et al., 1995) (Fig. 1).
Patients have greater difﬁculty in detecting a moving grat-
ing than a static one, which is a reversal of the normal
pattern where motion of a grating is detected before it
can be identiﬁed (Mestre et al., 1990; Haug et al., 1994).
Patients with Parkinson’s disease also have higher thresh-
olds than healthy controls for detecting the direction of
motion (Trick et al., 1994), although in a speed discrimin-
ation task, patients with Parkinson’s disease performed no
worse than controls (Mosimann et al., 2004). Finally, in a
structure from motion task, where volunteers detect an
object that is formed from the contrast of moving dots,
patients with Parkinson’s disease show higher thresholds
for correctly identifying objects (Uc et al., 2005).
Spatial neglect
Patients with Parkinson’s disease predominantly affecting
their left side show a rightward bias when bisecting a hori-
zontal line. (Lee et al., 2001b; Laudate et al., 2013). This
reﬂects spatial neglect on the left, ipsilateral to the side
affected by motor symptoms, and suggests involvement of
right parietal cortex. Line bisection bias is not seen in pa-
tients with right-sided Parkinson’s disease. Similarly, in line
cancellation tasks, patients with left-sided (but not right-
sided) Parkinson’s disease show impaired line cancellation
(Villardita et al., 1983). In a related phenomenon, patients
with left sided Parkinson’s disease perceive objects within
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their left visual ﬁeld as smaller than on the right (Harris
et al., 2003) and experience a reduced visual representation
of doorways (Lee et al., 2001a). This perceptual difference
may contribute mechanistically to the phenomenon of
freezing in doorways. In eye movement analyses, when
searching for a target, patients with left-sided Parkinson’s
disease will explore the right hemiﬁeld ﬁrst, in contrast
with healthy controls and patients with right-sided
Parkinson’s disease, who show a leftward bias (Ebersbach
et al., 1996). Similarly, patients with left-sided Parkinson’s
disease show longer latencies for saccades to left-sided tar-
gets compared to the right (Ventre et al., 1992). Whether
differences in spatial representation are caused by eye
movement abnormalities, or eye movements reﬂect the dif-
ferences in perception could be tested in future studies.
Face and emotion recognition
The ability to recognize faces is impaired in Parkinson’s
disease (Levin et al., 1991), with performance correlated
with grey matter density in the fusiform face area, the
region involved in face recognition in the heathy brain
(Pereira et al., 2009). There is particular difﬁculty in inter-
preting facial expressions (Sprengelmeyer et al., 2003), with
greater impairment for negative emotions including disgust
(Suzuki et al., 2006), sadness (Hipp et al., 2014) and fear
(Jacobs et al., 1995; Dujardin et al., 2004; Clark et al.,
2008; Gray and Tickle-Degnen, 2010). This greater deﬁcit
for emotional face processing in Parkinson’s disease may be
explained by the presence of two distinct face processing
pathways that are sensitive to different spatial frequency
ranges: face identiﬁcation, associated with the fusiform
face area, is more activated by high spatial frequency
ranges (detailed visual information). In contrast, subcortical
pathways, including the amygdala, are activated by fearful
faces, and are driven by coarse, low spatial frequency in-
formation (Vuilleumier et al., 2003). The ﬁnding that per-
formance improves in patients treated with L-DOPA is
consistent with the involvement of dopaminergic neurons
in this pathway (Sprengelmeyer et al., 2003).
Neurobiology underlying
visual changes: genetic basis
for heterogeneity
Important insights into the heterogeneity of Parkinson’s dis-
ease have emerged with the discovery in recent years of
genetic mutations that cause or predispose to Parkinson’s
disease, some of which are associated with deﬁned molecu-
lar pathways. Visual perceptual dysfunction associated with
speciﬁc mutations may therefore implicate potential patho-
physiological mechanisms. Patients carrying LRRK2 muta-
tions have better colour discrimination (Marras et al.,
2011) and fewer cognitive deﬁcits than patients with idio-
pathic Parkinson’s disease (Alcalay et al., 2013) (Table 1).
Parkinson’s patients who carry PARK2 mutations, which
are associated with dysfunction in the mitochondrial system
and have a more restricted distribution of neuropathology,
perform better in cognitive tests than patients with sporadic
Parkinson’s disease (Alcalay et al., 2014).
Conversely, patients with Parkinson’s disease that carry
mutations in the gene encoding the lysosomal enzyme glu-
cocerebrosidase (GBA) show deﬁcits in visuospatial tasks
(Alcalay et al., 2012), have impaired visual memory
(Zokaei et al., 2014) and show a higher frequency of
visual hallucinations (Neumann et al., 2009; Wang et al.,
2014) than patients with idiopathic Parkinson’s disease.
Intriguingly, patients with GBA mutations have decreased
cerebral blood ﬂow in the parietal lobe and precuneus
(Goker-Alpan et al., 2012), regions involved in visual per-
ception (Cavanna and Trimble, 2006) and in visual
memory (Kochan et al., 2011). Patients with Parkinson’s
disease that carry GBA mutations also show a higher fre-
quency of clinical features that are often associated with
visual dysfunction in Parkinson’s disease: they have a
higher risk of cognitive deﬁcits (Neumann et al., 2009;
Brockmann et al., 2011; Winder-Rhodes et al., 2013) and
rapid eye movement (REM) sleep disorder than patients
with idiopathic Parkinson’s disease (Beavan et al., 2015;
Gan-Or et al., 2015) (see below for further discussion of
clinical features associated with visual dysfunction in
Parkinson’s disease).
Patients with Parkinson’s disease carrying mutations in
the gene for synuclein, SNCA, also show higher rates of
cognitive deﬁcits, REM sleep behaviour disorder (RBD) and
hallucinations (Nishioka et al., 2009; Konno et al., 2016;
Petrucci et al., 2016). Neuropathological studies of these
patients show a greater -synuclein burden in the cerebral
cortex than in idiopathic Parkinson’s disease (Ikeuchi et al.,
2008; Obi et al., 2008) and ﬂuorodeoxyglucose (FDG)
signal is reduced in the occipital lobes (visual processing
regions) of patients carrying SNCA mutations compared
with controls (Nishioka et al., 2009). Both the GBA and
SNCA genes are linked with the lysosomal pathway
(Mazzulli et al., 2011), suggesting the visual deﬁcits asso-
ciated with these genes may share a pathophysiological
mechanism, with lysosomal dysfunction associated with
cortical visual dysfunction.
Genetic polymorphisms may also play a role in predis-
position to cognitive impairment in Parkinson’s disease. A
common polymorphism in MAPT has been linked to de-
mentia in Parkinson’s disease (Goris et al., 2007) and pa-
tients carrying the H1 MAPT polymorphism make more
errors in difﬁcult spatial rotation tasks, and show reduced
parietal cortex activity (Nombela et al., 2014).
The underlying mechanism for these ﬁndings may relate
to differences in the cortical expression of 4- versus 3-
repeat isoforms of tau (Williams-Gray et al., 2009).
Greater understanding of these genetic differences between
individuals will be crucial in future studies seeking to deﬁne
the explanations for the diversity in visuospatial function
found in Parkinson’s disease
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Clinical relevance
Clustering of symptoms with visual
dysfunction in Parkinson’s disease
There is an increasing acknowledgement of the clinical het-
erogeneity of idiopathic Parkinson’s disease (Selikhova
et al., 2009; Halliday et al., 2011; Sieber et al., 2014)
and differences in survival rates have been reported be-
tween clinical subtypes deﬁned in longitudinal analysis (de
Lau et al., 2014). Visual dysfunction frequently co-exists
with cognitive impairment, visual hallucinations, postural
instability with gait disorder and RBD (Davidsdottir
et al., 2005; Marques et al., 2010). Two distinct neuropsy-
chological syndromes have been proposed in Parkinson’s
disease: a frontal-striatal dopamine-mediated dysexecutive
syndrome that does not progress to dementia; and a
second form with prominent visuospatial and sematic ﬂu-
ency impairments that is more frequently associated with
decline to dementia. Therefore, recognizing visuospatial im-
pairment in the context of cognitive deterioration may have
importance as a prognostic marker for dementia in
Parkinson’s disease. (Williams-Gray et al., 2009; Kehagia
et al., 2010).
Relation with sleep abnormalities
Idiopathic RBD, characterized by loss of normal atonia
during REM sleep, is considered a risk factor for
Parkinson’s disease and other synucleinopathies: over
80% of idiopathic RBD patients may eventually develop
a neurodegenerative disorder linked to -synuclein accumu-
lation in the brain (Iranzo et al., 2013; Schenck et al.,
2013). Visuo-perceptual deﬁcits have been reported in pa-
tients with RBD (who have not yet developed Parkinson’s
disease), with impairments in colour vision and visuospatial
construction (Boeve et al., 1998; Ferini-Strambi et al.,
2004; Postuma et al., 2009; Manni et al., 2013). Those
RBD patients with sensory abnormalities at baseline
(including colour vision defects) have also been claimed
to develop a form of Parkinson’s disease with more prom-
inent cognitive involvement (Postuma et al., 2011). Later,
at mid-stage, this same association, RBD and poor colour
discrimination, is again linked with a more rapid and ag-
gressive disease course (Fereshtehnejad et al., 2015).
Although RBD is a rare prodromal sign in patients present-
ing with motor symptoms, up to a third of patients develop
RBD in the course of their illness (Gagnon et al., 2002;
Manni et al., 2010). When it occurs, it is associated with
visuo-perceptual dysfunction, including errors in object rec-
ognition (Marques et al., 2010) and complex ﬁgure copying
(Vendette et al., 2007). The presence of RBD in Parkinson’s
disease is also predictive of progressive cognitive dysfunc-
tion (Sinforiani et al., 2008; Postuma et al., 2012; Nomura
et al., 2013).
The recent discovery of a novel photoreceptor system in
the retina may provide a further link between sleep and
visual dysfunction in Parkinson’s disease. A subset of ret-
inal ganglion cells, known as melanopsin photoreceptors,
are believed to play a role in regulating circadian rhythms.
Dysfunction of these retinal ganglion cells, possibly by -
synuclein deposition, or by a change in dopamine levels,
causes unopposed melatonin production, with subsequent
effects on sleep (for a review see Schmoll et al., 2011).
Furthermore, the projection of these cells to brain regions
involved in circadian and sleep functions as well as to
visual areas such as the lateral geniculate nucleus may ex-
plain some of the daytime-dependent (not just luminance-
dependent) visual symptoms of Parkinson’s disease (La
Morgia et al., 2011).
Gait, postural instability and tremor
Visual perceptual deﬁcits are frequently associated with the
postural instability and gait disorder phenotype (PIGD).
Visual abnormalities are more common in patients with
freezing of gait (Davidsdottir et al., 2005) and correlate
with the severity of gait impairment (Uc et al., 2005).
Furthermore, visual contrast sensitivity predicts severity of
freezing, independent of duration or severity of disease
(Davidsdottir et al., 2005). In patients with freezing of
Table 1 Associations between features linked with visual dysfunction and common Parkinson’s disease-associated
genetic mutations
Potential
pathway
Gene Performance compared with
idiopathic Parkinson’s disease
Frequency compared with
idiopathic Parkinson’s disease
Colour vision Cognitive
performance
Visual
hallucinations
RBD
Multiple implicated LRRK2 Increaseda Increasedb Decreasedc Decreasedd
Mitochondrial PARK2 Increasede Increasedf Not known Similarg
Lysosomal GBA Possibly increasedh Decreasedi Increasedj Increasedk
Lysosomal SNCA Not known Decreasedl,m Increasedl,m Increasedl,n
aMarras et al., 2011; bAlcalay et al., 2013; cSomme et al., 2015; dEhrminger et al., 2015; eKertelge et al., 2010; fAlcalay et al., 2014; gSixel-Doring et al., 2015; hSimon-Tov et al., 2015;
iAlcalay et al., 2012; jNeumann et al., 2009; kGan-Or et al., 2015; lKonno et al., 2016; mPetrucci et al., 2016; nNishioka et al., 2009.
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gait, step length reduces on going through narrow door-
ways, suggesting a perceptual mechanism interfering with
movement planning (Almeida and Lebold, 2010; Cowie
et al., 2010).
Conversely, the tremor predominant phenotype is
less associated with visual deﬁcits. In questionnaire
studies, patients without tremor report worse visual func-
tion (Seichepine et al., 2011). Patients with increased
tremor perform better on tasks of line orientation, men-
tal reconstruction and rotation tasks (Levin et al.,
1991) and in longitudinal follow-up, presence of
tremor is associated with a more benign course and
fewer colour vision abnormalities (Fereshtehnejad et al.,
2015).
The link between visual perceptual deﬁcits and gait
abnormalities may be partly explained by the critical role
of vision in balance (Day and Guerraz, 2007). Patients with
Parkinson’s disease show a higher dependence on visual
information for motor and postural control (Bronstein
et al., 1990). This may have a therapeutic role as it has
been shown that visual cueing can improve walking in
Parkinson’s disease (Stern et al., 1980; Azulay et al.,
1999; Lewis et al., 2000). However, the association of
visual deﬁcits with the akinetic rigid phenotype and relative
sparing of visual dysfunction in the tremor predominant
phenotype may also reﬂect distinct pathophysiological pat-
terns of disease.
Hallucinations: links with
visuo-perceptual deficits
Visual hallucinations are common in Parkinson’s disease,
with a prevalence of 30% (Holroyd et al., 2001). Their
presence is believed to be highly speciﬁc for Lewy body
pathology (Williams et al., 2008), and can be helpful in
distinguishing between Parkinson’s disease and other par-
kinsonian syndromes such as multiple system atrophy
(MSA-P) and progressive supranuclear palsy (PSP-P)
(Williams and Lees, 2005). Visual hallucinations often
occur in poor lighting and are associated with reduced
visual acuity (Holroyd et al., 2001; Matsui et al., 2006;
Archibald et al., 2011) but can also be seen in patients
with normal visual acuity (Diederich et al., 1998; Biousse
et al., 2004). They are also associated with impaired con-
trast sensitivity and colour vision (Diederich et al., 1998)
and patients with visual hallucinations show greater deﬁcits
in object and face identiﬁcation compared to those without
hallucinations (Barnes et al., 2003; Ramirez-Ruiz et al.,
2006; Gallagher et al., 2011), reﬂecting involvement of
higher cortical visual dysfunction. Recent reports of
minor visual hallucinations in patients at the earliest
stages of Parkinson’s disease (Pagonabarraga et al.,
2016), including in untreated patients, lends further sup-
port for changes in cortical visual processing even at the
initial stages of Parkinson’s disease.
Mechanistic considerations of minor
hallucinations
‘Passage hallucinations’ are illusions of objects, commonly
insects and small animals, moving across the peripheries of
vision (Fenelon et al., 2000). The combination of being
more sensitive to irrelevant peripheral objects (McDowell
and Harris, 1997a), and less able to discriminate details in
the periphery could explain this phenomenon.
Misinterpretations, or illusions, where innocuous objects
such as piles of clothes are misidentiﬁed as animals, are
also commonly reported in Parkinson’s disease. These
may be generated by similar mechanisms of increased sen-
sitivity but reduced discriminatory ability for objects in per-
ipheral vision.
The phenomenon of blindsight might also help to explain
minor illusions in Parkinson’s disease (Diederich et al.,
2014). Blindsight is the syndrome of retained visual abilities
in patients with bilateral occipital damage who can accur-
ately guess locations of objects in space despite the absence
of conscious visual perception. It is mediated via alternate
visual pathways from the retina, involving the thalamus,
colliculus and amygdala and is a form of unconscious pro-
cessing of visual information. It has been suggested that
these alternate pathways are damaged in Parkinson’s dis-
ease, rendering patients ‘blind to blindsight’ (Diederich
et al., 2014). According to the model, patients with
Parkinson’s disease have difﬁculty guessing locations in per-
ipheral space, which may lead to the erroneous experience
of objects in the lateral ﬁeld. This conceptual framework
may explain minor illusions but it cannot account for com-
plex visual hallucinations that arise in the absence of any
stimulus and at the point of ﬁxation.
Mechanistic considerations of
complex hallucinations
The complex visual hallucinations reported in Parkinson’s
disease almost invariably involve animate objects, are often
at ﬁxation and are more frequently experienced in dim
light. They are usually non-frightening and occasionally
enjoyed, but become increasingly distressing over time
(for reviews see Fenelon et al., 2000; Diederich et al.,
2009; Collerton et al., 2015). Previous models to explain
these hallucinations include cortical irritation caused by
electrical over-activity in brain regions containing images
(Levine and Finklestein, 1982). However, there is no evi-
dence for cortical irritation in Parkinson’s disease and com-
plex hallucinations are not strongly associated with diseases
where cortical irritation is a feature, such as epilepsy.
A more attractive model considers hallucinations as ‘cor-
tical release’ phenomena (Ffytche and Howard, 1999). In
this model, that has also been used to explain the hallucin-
ations seen in Charles Bonnet syndrome, stimulus-driven
bottom-up visual processing is inhibitory in nature and
when absent, this releases spontaneous activity. Visual
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hallucinations therefore arise from a lack of sensory input
that leads to the release of stored images. However, loss of
visual input alone, from eye disease or stroke, only infre-
quently leads to visual hallucinations and the visual deﬁcits
seen in Parkinson’s disease are not profound enough to
cause absent sensory input.
Collerton and colleagues (2005) have proposed a
Perception and Attention Deﬁcit model based on proto-ob-
jects that are part of normal scene perception. These are
object templates from higher visual processing regions pro-
jected to lower visual regions during normal scene percep-
tion. In health, visual input activates several competing
proto-objects but attentional binding allows only one
object to be perceived. During hallucinations, impaired sen-
sory input causes activation of an incorrect proto-object.
This, combined with impaired attentional binding, causes
it to be incorrectly projected onto the intact visual scene.
Although the combination of early perceptual deﬁcits with
higher attentional networks is likely to be important in
generating visual hallucinations, this model has limitations.
It cannot adequately explain the appearance of incongruent
objects during hallucinations. It also implies that properly
perceived objects should displace hallucinatory objects,
causing the hallucination to disappear, which does not
occur [see commentary by Morrison and David (2005) on
Collerton et al., 2005)].
The Activation-Input-Modulation model proposed by
Hobson, is another hypothesis (Hobson et al., 2000;
Diederich et al., 2005). The ﬁrst dimension, activation, re-
lates to level of alertness; the second is input, or sensory
information. The third dimension, modulation, is the inte-
gration of the ﬁrst two dimensions over time and invokes
aminergic and cholinergic transmission. According to this
model, movement along each dimension increases the like-
lihood for visual hallucinations. In this way, aberrant visual
processing increases the propensity for visual hallucin-
ations, as would changes in arousal levels. The modulation
dimension is affected by pharmacological inﬂuences. One
weakness of the model is that it fails to explain how visual
hallucinations that are initially benign can become increas-
ingly distressing with loss of insight.
Visual hallucinations in Parkinson’s disease have also
been claimed to be due to breakdown in the connectivity
in the neural networks subserving attention and conscious
perception (Shine et al., 2014) (Fig. 3). These comprise the
Dorsal Attention Network (DAN), the Ventral Attention
Network (VAN) and the Default Mode Network (DMN).
The DAN is activated during tasks requiring exogenous
attention. The DMN is associated with internally focused
tasks, e.g. mind wandering, whereas the VAN is used for
salience monitoring and mediates the switch between the
DAN and the DMN. The attentional networks hypothesis
predicts that visual hallucinations in Parkinson’s disease are
caused by overactivity of the DMN and VAN reinforcing
false images that are then unchecked due to failure to
engage the DAN. This leads to over reliance on the
DMN and VAN that are poorly suited to interpret ambigu-
ous sensory images.
Change in visual perceptual function seems at least ne-
cessary, if not sufﬁcient, for complex hallucinations. Visual
dysfunction is more common in Parkinson’s disease pa-
tients experiencing hallucinations (Gallagher et al., 2011)
and in neuroimaging studies, glucose consumption is
reduced in occipito-temporal regions in Parkinson’s patients
with visual hallucinations compared to those without
(Boecker et al., 2007). Executive dysfunction may also
have a role in mediating visual hallucinations: Parkinson’s
patients with hallucinations perform worse on tests of ex-
ecutive function compared to those without visual hallucin-
ations (Grossi et al., 2005; Barnes and Boubert, 2008; Shin
et al., 2012) and higher cortical Lewy body density is seen
in the middle frontal gyrus in patients with visual hallucin-
ations (Harding et al., 2002; Papapetropoulos et al., 2006).
Structural neuroimaging shows grey matter atrophy in the
medial frontal lobe in Parkinson’s disease patients with
visual hallucinations compared to those without
(Ramirez-Ruiz et al., 2007; Goldman et al., 2014) as well
as in visual processing regions. Hallucinations are difﬁcult
to capture using functional neuroimaging due to their tran-
sient nature, but a recent study has shown increased acti-
vation in frontal regions and decreased activation in visual
cortex (Goetz et al., 2014), although no correction for
Figure 3 Theories for visual hallucinations in Parkinson’s
disease. The attention networks hypothesis for visual hallucin-
ations in Parkinson’s disease (Shine et al., 2014). The DAN (involving
dorsolateral prefrontal cortex and posterior parietal cortex) is
engaged in voluntary orienting; the VAN (involving the lateral and
inferior prefrontal cortex and amygdala) engages attention to salient
stimuli and mediates activation of other networks; the DMN
(involving the medial temporal and medial prefrontal cortex) is
engaged in task independent introspective tasks); VIS = visual
cortex, processing of visual information. In this model, visual hallu-
cinations are caused by over-reliance on the DMN and the VAN in
processing ambiguous percepts, with relative inability to recruit the
DAN. Adapted from Shine et al. (2015) with permission.
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multiple comparisons was reported, making the data difﬁ-
cult to interpret. The prevailing models could provide a
framework for the conjunction of visual perceptual deﬁcits
with frontal executive dysfunction seen in patients with
Parkinson’s disease who experience complex hallucinations.
Drug modulation of visual symptoms
Parkinson’s drugs can improve ophthalmic visual process-
ing. L-DOPA enhances colour vision and contrast sensitivity
in Parkinson’s disease (Bulens et al., 1987; Buttner et al.,
1994) and abnormal visual evoked potentials in patients
with Parkinson’s disease improve with L-DOPA (Bodis-
Wollner and Yahr, 1978), supporting a dopaminergic
basis for these deﬁcits in the lower visual pathways. On
the other hand, the effects of L-DOPA on higher visual
function are less well documented. Emotional face recogni-
tion improves with L-DOPA (Sprengelmeyer et al., 2003),
but effects of L-DOPA or other Parkinson’s drugs, on other
aspects of cortical visual processing are not known.
The effects of Parkinsonian drugs on visual hallucinations
associated with Parkinson’s disease are also not fully estab-
lished. Early reports correlated the incidence of visual hal-
lucinations with dose and duration of treatment with
L-DOPA (Sweet et al., 1976; Weiner et al., 1980).
However, recent reports are more equivocal. Some groups
found no difference in L-DOPA dose or duration between
patients with Parkinson’s disease with and without hallu-
cinations (Diederich et al., 1998). Off period visual hallu-
cinations are a recognized, if rare, phenomenon in
L-DOPA-treated patients with motor ﬂuctuations (Steiger
et al., 1991). Others found that while patients with hallu-
cinations were on a slightly higher daily dose of L-DOPA,
their levodopa equivalent dose was no different (Fenelon
et al., 2000). A recent study reported that a higher propor-
tion of patients with visual hallucinations were taking
L-DOPA (Gallagher et al., 2011) and no association was
found with other parkinsonian medications. However,
double-blind controlled trials with dopamine agonists con-
sistently show a higher rate of hallucinations than on pla-
cebo or L-DOPA (Poewe, 2003; Baker et al., 2009;
Bonuccelli et al., 2009; Kulisevsky and Pagonabarraga,
2010; Zhou et al., 2014). The conventional approach to
treatment of visual hallucinations reﬂects this by slowly
withdrawing dopamine agonists (Connolly and Lang,
2014). Anticholinergic drugs are a well-recognized cause
of visual hallucinations and delirium in elderly patients
with Parkinson’s disease (Goetz et al., 1982). Amantadine
is also hallucinogenic and both drugs should be withdrawn
when hallucinations occur (Postma and Van, 1975).
Impact on driving
There is a relation between contrast sensitivity and driving
performance in Parkinson’s disease and between visual per-
ception and driving ability, particularly in tests measuring
visual attention, motion perception and visuospatial
construction (Uc et al., 2006, 2009; Devos et al., 2013;
for a review see Crizzle et al., 2012). The postural instabil-
ity and gait disorder phenotype is predictive of poorer on-
road driving performance, beyond motor severity scores
(Devos et al., 2013), consistent with the association of
visuo-perceptual deﬁcits with this phenotype. Although
visuo-perceptual tests are useful predictors of driving abil-
ity, there is insufﬁcient evidence for them to be used alone
to determine driver safety. General advice is to consider
visuo-perceptual ability and if there is any doubt, to refer
the patient for a formal driving assessment via the national
driving authority (Crizzle et al., 2012).
The role of visuo-perceptual
changes as a marker for
disease
Visuo-perceptual measures as
diagnostic markers of Parkinson’s
disease
Changes in visual performance may be a sensitive marker
of Parkinson’s disease. In one study, deﬁcits in colour and
contrast sensitivity were shown to have better discrimin-
atory power for early diagnosis of Parkinson’s disease
than any other non-motor symptom, including hyposmia
and sleep disturbance, in patients within 3 years of diagno-
sis (Diederich et al., 2010). One theory of disease progres-
sion in Parkinson’s disease has suggested that the cerebral
cortex is not damaged until the later stages of the disease
(Braak et al., 2004). Although the exact pathological cor-
relates of colour and contrast sensitivity changes are un-
clear, changes in visual perception at the earliest stages of
the disease raise concerns about this notion. It is likely that
visual measures will be a useful marker of early disease
only in speciﬁc subgroups of patients with Parkinson’s dis-
ease (such as those with prominent early cognitive involve-
ment). Visuo-perceptual deﬁcits (unlike oculomotor
changes) are rarely reported in atypical forms of parkinson-
ism such as progressive supranuclear palsy, multiple system
atrophy or corticobasal syndrome. Visual processing
abnormalities may prove helpful in differentiating these
other diseases from idiopathic Parkinson’s disease.
Visuo-perceptual measures as
predictors of dementia in
Parkinson’s disease
Visual function may be important in predicting dementia in
Parkinson’s disease. In a prospective study, abnormal
colour vision at baseline tripled the odds of developing
dementia (Anang et al., 2014). In newly diagnosed patients
with Parkinson’s disease, impaired pentagon copying at
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diagnosis was a strong predictor for development of de-
mentia at 5- (Williams-Gray et al., 2009) and 10-year
follow-up (Williams-Gray et al., 2013) and pentagon copy-
ing deﬁcits show power to predict dementia even at 2-year
follow-up (Kaul and Elble, 2014). Similarly, patients with
new multi-domain dementia at 3-year follow-up showed
impaired performance in an overlapping ﬁgures test at
baseline (Shoji et al., 2014). These ﬁndings are supported
by functional neuroimaging ﬁndings: in a longitudinal
FDG-PET study of Parkinson’s disease, patients who de-
veloped dementia, showed occipito-parietal hypometabo-
lism at baseline (Bohnen et al., 2011). However,
pentagon copying involves multiple cognitive domains
including executive function, praxis and motor planning
areas, in addition to visuo-perceptual processes, making it
difﬁcult to make conﬁdent claims regarding the role for
visual perception in dementia prediction.
Visual symptoms may also predict outcome. Visual hal-
lucinations are strong predictors for nursing home place-
ment (Goetz and Stebbins, 1993) and have been suggested
as a harbinger for the onset of dementia in Parkinson’s
disease (Santangelo et al., 2007). In nursing home residents
with Parkinson’s disease, the presence of visual problems is
a predictor of mortality (with age, cognitive impairment
and pressure ulcers also predictive) (Fernandez and
Lapane, 2002). Identifying the presence of visuo-perceptual
deﬁcits may therefore have a critical role in stratifying pa-
tients in the clinic for early treatment with cholinesterase
inhibitors and for deﬁning enriched populations for disease-
modifying interventions in clinical trials aimed at prevent-
ing dementia in Parkinson’s disease.
Optical coherence tomography for
measuring disease presence and
progression
Optical coherence tomography enables high resolution
structural imaging of the retina, with measurement of all
retinal layers, in vivo. Recent technical advances have led
to increasing interest in the role of the retina in monitoring
disease activity in Parkinson’s disease (Bodis-Wollner et al.,
2014b; Lee et al., 2014a). The nerve ﬁbre layer is thinned
in Parkinson’s disease (Inzelberg et al., 2004; Altintas et al.,
2008) and at the macula, thinning is found in the inner
retinal layer (Hajee et al., 2009; Shrier et al., 2012).
Interocular differences are seen in retinal thickness in
Parkinson’s disease (Shrier et al., 2012) with more thinning
contralateral to the side of motor symptoms (La Morgia
et al., 2013), consistent with an asymmetric process invol-
ving the eye on the same side as the affected substantia
nigra. Recently, retinal morphology, measured using optical
coherence tomography, combined with visual electrophysi-
ology was shown to have high diagnostic yield in
Parkinson’s disease (Miri et al., 2016). A correlation be-
tween retinal thickness, disease severity (Altintas et al.,
2008; Miri et al., 2015) and duration (Miri et al., 2015;
Sari et al., 2015) has been reported in some but not all
studies (La Morgia et al., 2013). In Parkinson’s disease
dementia, there is a correlation between retinal thickness
and Mini-Mental State Examination scores (Moreno-
Ramos et al., 2013), although this is not found in patients
without dementia (Garcia-Martin et al., 2012). Whether
this reﬂects insensitivity of the Mini-Mental State
Examination, or an absence of relationship between demen-
tia and retinal thickness is not yet known. Intriguingly,
retinal thinning is associated with presence of minor hallu-
cinations (Lee et al., 2014b), although this was not found
for patients with complex visual hallucinations, consistent
with the involvement of higher cognitive domains in these
hallucinations. Optical coherence tomography therefore
shows promise as a potential biomarker for presence of
disease in Parkinson’s disease, but more studies will be
needed to assess the role of the retina in predicting demen-
tia in Parkinson’s disease.
Neuroimaging signatures of visual
dysfunction as a marker of disease in
Parkinson’s disease
Structural and functional neuroimaging studies are consist-
ent with early involvement of cortical visual processing re-
gions in Parkinson’s disease. Cortical thinning in the
occipital cortex, measured using MRI, correlates with dis-
ease duration (Jubault et al., 2011), with maximal cortical
thinning seen in the lateral occipital complex and parietal
regions (Pereira et al., 2012). Metabolic deﬁcits have been
reported using PET in occipital cortex (Eberling et al.,
1994; Bohnen et al., 1999) and occipital and parietal hypo-
perfusion in Parkinson’s disease can be detected by measur-
ing regional cerebral blood ﬂow (Abe et al., 2003), that
worsens with disease progression (Nagamachi et al.,
2008). Arterial spin labelled perfusion MRI, a non-invasive
measure of perfusion, similarly shows regions of perfusion
deﬁcit in early stages of Parkinson’s disease affecting fron-
tal, parietal and also occipital brain regions (Fernandez-
Seara et al., 2012).
Recently, network approaches have been applied to struc-
tural and functional MRI data in Parkinson’s disease.
These reveal changes in patterns of connectivity between
brain regions and strongly implicate early involvement of
visual processing regions in Parkinson’s disease. Reduced
connectivity is seen in temporo-occipital regions, using rest-
ing state functional MRI in patients within 3 years of diag-
nosis, with connectivity losses strongly correlated with
reduced visuospatial performance (Luo et al., 2015). In pa-
tients at mid-stage Parkinson’s disease, resting state func-
tional MRI network analysis shows connectivity changes
especially affecting visual regions (Gottlich et al., 2013).
In Parkinson’s disease patients with mild cognitive impair-
ment, the efﬁciency of connections in parietal, as well as
frontal regions is reduced (Pereira et al., 2015), consistent
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with involvement of visuo-perceptual processing brain re-
gions in the early stages of dementia in Parkinson’s disease.
Conclusion and future
directions
Alterations in visual function from the retina to higher cor-
tical brain regions have been found in Parkinson’s disease,
with some aspects of visuo-perceptual processing worsening
with disease progression (Diederich et al., 2002; Gullett
et al., 2013) and there are emerging data showing impaired
pentagon copying as one of the earliest cognitive deﬁcits in
Parkinson’s disease. There are, however, no studies of the
power of other markers of visuo-perpetual function to pre-
dict dementia in Parkinson’s disease. Further studies exam-
ining visuo-perceptual function in Parkinson’s disease are
required to correlate performance with other disease fea-
tures such as laterality of motor symptoms and with clinical
phenotypes such as postural instability or tremor predom-
inance. Visuo-perceptual performance also needs to be cor-
related with common Parkinson’s disease-associated genetic
mutations to gain insights into pathophysiological path-
ways underlying deﬁcits; and with neuroimaging to link
visuo-perceptual impairment with anatomical regions.
These future combined approaches should enhance under-
standing of the mechanisms underlying progression of
Parkinson’s disease to involve cognition.
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